trial

N-acetylcysteine Effects on Tetrahydrocannabinol

NCTId NCT02335060
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Early Phase 1 · Terminated
Enrollment 5 (actual)
Sponsored by Yale University
Primary completion 2014-09-16
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Early Phase 1
Status
Terminated
Enrollment
5 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2014-05-02
Primary completion
2014-09-16
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Delta-9-THCN-acetylcysteine

Sponsors

Yale UniversityLead Sponsor

Investigators

1
Mohini Ranganathan, MBBSPrincipal Investigator

Sites

1 total
West Haven, United States

Facts & assertions

4 sourced
Enrollment
5
Phase
EARLY_PHASE1
Primary Completion Date
2014-09-16
Status
TERMINATED
relationships
The graph out of here
drug
Delta-9-THC
drug
N-acetylcysteine
drug
lead_sponsor
Yale University
company
indication
Psychotic Disorders
indication
Healthy
indication
Marijuana Abuse
indication
investigator
Mohini Ranganathan, MBBS
person